Release Date: December 22, 2014 | Expiration Date: December 22, 2015
Media: Print with online posttest, evaluation, and request for credit
OverviewThe International Lung Cancer Congress® was held July 31 to August 2 in Huntington Beach, CA. The meeting serves as an update on advances in the lung cancer field with a focus on the clinical implications of the rapid changes in treatment options--novel agents, strategies, and improved regimens. The State of the Art segment of the agenda focused on the key treatment areas--novel agents, molecular testing, and maintenance therapy. This article reviews anti-angiogenetic therapy, next-generation EGFR TKIs, ALK inhibitors, acquired resistance, and maintenance therapy, providing physicians who could not attend the live meeting the opportunity to engage in the education.
Instructions For This Activity & Receiving Credit
This activity is directed toward medical oncologists and hematologists who treat patients with solid tumors and hematologic malignancies. Fellows, nurses, physician assistants, nurse practitioners, and other healthcare providers may also participate.
After participating in this CME activity, learners should be better prepared to:
- Discuss strategies to improve care for patients with lung cancer
- Review current standards and emerging data regarding systemic therapies for the treatment of advanced non-small cell lung cancer
Disclosure: No relevant financial relationships with commercial interests to disclose.
Debu Tripathy, MD
The American Journal of Hematology/Oncology Editorial Board Member
Professor of Medicine and Chair
Department of Breast Medical Oncology
The University of Texas MD Anderson Cancer Center
Disclosure: Genentech/ Roche, Pfizer, Puma, Inc. (clinical trial support contracted to University of Southern California); Consultant: Eisai, Novartis
The staff of PER® (Debbie Augustus, Ann C. Lichti, CCMEP and Megan O'Connell) as well as the Editorial Staff of The American Journal of Hematology/Oncology (Devera Pine) have no relevant financial relationships with commercial interests to disclose.
Staff/Planner Disclosures and Conflict of Interest Resolution
In accordance with ACCME's Standards for Commercial SupportSM, PER® resolved all conflicts of interest (COI) prior to the release of this CME activity using a multistep process.
Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Acknowledgment of Commercial Support
This activity is funded entirely by Physicians’ Education Resource®.
This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical education purposes only, and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options for a specific patient's medical condition.
Off-Label Disclosure and Disclaimer
The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER®.
Hardware And Software Requirements
Internet Explorer v.7 or greater (for Windows) | Mozilla Firefox v.2 or greater (for Windows, Mac, Linux)
Minimum System Requirements (Windows)
- A Pentium-based PC or compatible computer
- At least 64MB of RAM
- Windows 95/98/NT/ME/2000/XP/Vista system software
- Screen resolution of 1024 x 786 or larger recommended
- PDF Reader: Adobe Reader 5.0 or higher, Foxit Reader 2.0 or likewise